Biopharmaceutical company CV Therapeutics Inc. said Tuesday its angina drug ranolazine, or Ranexa, showed no adverse trend in deaths or arrhythmias, but failed to meet its goal in a late stage study.
The drug is already approved as a second-line treatment for chronic angina.
The company said a Phase III clinical trial studying the drug for other uses as a treatment of coronary syndromes did not meet its primary study goal for effectiveness. But the safety results gathered from the study could support expansion of the drug into a first-line treatment.
Full results will be released March 27 at the American College of Cardiology Scientific Session in New Orleans, the company said.
Shares of CV Therapeutics rose 10 cents to close at $12.30 on the Nasdaq Stock Market.
CVTX in after hours trading, plunged down over 27% or $3.34 to a price of 8.96 a share.
Electrical excitation in cardiac cells causes sodium ions to enter the cell through membrane sodium channels.
Ranolazine used for angina works by reducing sodium entry into cardiac cells through those sodium channels. As a result, it improves sodium and calcium homeostasis and contractile function and balancing out ions that are the end result of ischemia.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment